Shifting from megamergers to strategic collaboration: M&A in biopharma
Will 2021's trend of high volume but small value merger and acquisition (M&A) deals continue in 2022? Subin Baral, EY Global Life Sciences Deals Leader discusses what is motivating the recent changes in M&A contracts.
Source: europeanpharmaceuticalreview.com